Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS)
Go back to Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS)| ENDOCYTE (NASDAQ: ECYT) | Delayed: 23.99 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.99 | 52 Week High | $4.89 | |||
| Open | $25.06 | 52 Week Low | $2.62 | |||
| Day High | $23.99 | P/E | N/A | |||
| Day Low | $23.99 | EPS | $-0.44 | |||
| Volume | 0 | |||||
